Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Rating of “Hold” by Brokerages

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) have earned a consensus recommendation of “Hold” from the fourteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $40.70.

A number of equities analysts have issued reports on the company. Truist Financial downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target on the stock. in a research report on Monday, April 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Monday, April 20th. Wolfe Research downgraded Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Guggenheim lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 2nd. Finally, Lifesci Capital lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA opened at $39.64 on Tuesday. Centessa Pharmaceuticals has a 12 month low of $10.95 and a 12 month high of $40.26. The stock has a fifty day moving average price of $35.53 and a 200-day moving average price of $28.96. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. The firm has a market cap of $5.92 billion, a PE ratio of -22.15 and a beta of 1.13.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). Equities research analysts predict that Centessa Pharmaceuticals will post -1.65 earnings per share for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In related news, insider Gregory M. Weinhoff sold 73,196 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider directly owned 65,925 shares of the company’s stock, valued at approximately $1,735,805.25. This trade represents a 52.61% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Karen M. Anderson sold 120,029 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the completion of the transaction, the insider directly owned 62,085 shares in the company, valued at $1,629,731.25. This represents a 65.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 309,112 shares of company stock worth $8,424,535 over the last ninety days. 4.09% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. TD Waterhouse Canada Inc. purchased a new position in Centessa Pharmaceuticals in the 4th quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth approximately $36,000. T. Rowe Price Investment Management Inc. increased its holdings in shares of Centessa Pharmaceuticals by 7,580.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after buying an additional 1,516 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after buying an additional 1,008 shares during the last quarter. Finally, Knott David M Jr acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth approximately $100,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.